Singapore markets closed

Glaukos Corporation (GKOS)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
96.68+1.55 (+1.63%)
As of 01:09PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close95.13
Open95.00
Bid0.00 x 800
Ask0.00 x 800
Day's range95.67 - 98.70
52-week range45.38 - 102.33
Volume314,415
Avg. volume682,254
Market cap4.852B
Beta (5Y monthly)1.10
PE ratio (TTM)N/A
EPS (TTM)-2.78
Earnings date01 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est106.55
  • Business Wire

    Glaukos Announces the Release of its 2023 Sustainability Report

    ALISO VIEJO, Calif., April 16, 2024--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has published its 2023 Sustainability Report. The report highlights the company’s continued commitment and progress on its key corporate sustainability initiatives. The Sustainability Report can be found on the company’s website here.

  • Zacks

    Here's Why You Should Retain Glaukos (GKOS) Stock for Now

    Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

  • Zacks

    Glaukos (GKOS) Gains Nearly 25% YTD: What's Driving the Rally?

    Glaukos' (GKOS) shares have risen year to date on the back of strong fundamentals. However, rising costs can be a cause of concern.